menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nepafenac","moa":"||COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"||COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Harrow \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"L.V. Prasad Eye Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nepafenac","moa":"||Cyclooxygenase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"L.V. Prasad Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"L.V. Prasad Eye Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"L.V. Prasad Eye Institute \/ Allergan"}]

    Find Clinical Drug Pipeline Developments & Deals for ILEVRO

    Menu

    ILEVRO

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Harrow

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Wil...

                            Details : Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.

                            Product Name : Ilevro

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            EPSC
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Harrow

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to Ilevro®, Nevanac®, Vigamox®, Maxidex®, An...

                            Details : Ilevro® (nepafenac ophthalmic suspension) is a 0.3%, a non-steroidal, anti-inflammatory eye drop indicated for pain and inflammation associated with cataract surgery.

                            Product Name : Ilevro

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Harrow

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            L.V. Prasad Eye Institute

                            Country arrow
                            EPSC
                            Not Confirmed

                            L.V. Prasad Eye Institute

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Silverstein Eye Centers

                            Country arrow
                            EPSC
                            Not Confirmed

                            Silverstein Eye Centers

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bromfenac,Nepafenac

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Opht...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2019

                            Lead Product(s) : Bromfenac,Nepafenac

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actavis Inc

                            Ireland arrow
                            EPSC
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 17, 2018

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mati Therapeutics

                            Country arrow
                            EPSC
                            Not Confirmed

                            Mati Therapeutics

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammat...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 12, 2018

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Intuor Technologies

                            Country arrow
                            EPSC
                            Not Confirmed

                            Intuor Technologies

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 20, 2017

                            Lead Product(s) : Nepafenac,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MDbackline, LLC

                            Country arrow
                            EPSC
                            Not Confirmed

                            MDbackline, LLC

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Alcon Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 27, 2016

                            Lead Product(s) : Nepafenac,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Alcon Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Carolina Eyecare Physicians, LLC

                            Country arrow
                            EPSC
                            Not Confirmed

                            Carolina Eyecare Physicians, LLC

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide,Moxifloxacin,Vancomycin Hydrochloride,Nepafenac,Moxifloxacin Hydrochloride,Prednisolone Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Science in Vision

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dropless vs. Standard Drops Contralateral Eye Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2015

                            Lead Product(s) : Triamcinolone Acetonide,Moxifloxacin,Vancomycin Hydrochloride,Nepafenac,Moxifloxacin Hydrochloride,Prednisolone Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Science in Vision

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alcon Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac,Prednisolone Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nepafenac Once Daily for Macular Edema - Study 2

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 07, 2013

                            Lead Product(s) : Nepafenac,Prednisolone Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth